Tesofensine: What the Research Says About the Triple Reuptake Inhibitor
Tesofensine is a compound that has drawn research attention in the metabolic space, with a mechanism quite different from the GLP-1 peptides dominating recent headlines. Here is a grounded overview of what the published research describes.
What is tesofensine?
Tesofensine is a small molecule described in the literature as a triple monoamine reuptake inhibitor, acting on noradrenaline, dopamine, and serotonin pathways. This central mechanism distinguishes it from incretin-based compounds such as semaglutide and tirzepatide.
How its mechanism differs
Because it works on monoamine signalling rather than incretin receptors, tesofensine is studied as a mechanistically separate approach within metabolic research. It is a small molecule, not a peptide, so its handling and stability profile differ from lyophilized peptides.
What the research describes
In published clinical research, tesofensine has been studied for effects on body weight over the trial periods examined. As with any investigational compound, findings vary by dose and study design, and it remains an unapproved research compound.
Where it sits in the field
For researchers comparing mechanisms, tesofensine represents the monoamine-reuptake angle alongside the incretin agonists covered in our GLP-1 agonist guide and the metabolic research roundup.
Handling and storage
Research compounds are kept according to their specific stability requirements; peptides in this space are typically supplied lyophilized and reconstituted with bacteriostatic water. See our reconstitution guide for general handling.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.